

EXPRESS MAIL No.: EV 168 506 US

I hereby certify that this correspondence is being deposited with the United States Postal Service Express mail under 37 CFR 1.10 on the date indicated above and is addressed to: Commissioner for Patents, Washington, DC 20231

By: *Ruth Montalvo* / Ruth Montalvo

Date: November 4, 2002

03C0  
Box See

In the event that this paper is late filed and a necessary Petition for an Extension of Time is not concurrently filed herewith, please consider this as a Petition for the requisite extension of time, and to the extent not tendered by check attached hereto, authorization to charge the extension fee, or any other fee required in connection with this paper, to Deposit Account No. 50-1529.

NOV 04 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Customer No. 026418

Docket No. JG-YY-5032C/500569.20090

Applicant(s): Tadahisa SATO, et al

Application No.: 10/042,703 Group:

Filed: March 21, 2002 Examiner:

For: DNA CHIP AND ITS PREPARATION

Commissioner for Patents  
Washington, D. C. 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR  
AMINO ACID SEQUENCE DISCLOSURES

Sir:

Applicant submits herewith the following in order to complete the above application:

- Executed Declaration and Power of Attorney.
- Verified English Translation.
- Applicant is entitled to claim Small Entity Status [See 37 CFR 1.27].
- Priority Document(s) No(s).
- The priority(ies) of which is(are) claimed under 35 USC 119.
- Other: A substitute computer readable form copy of the Sequence Listing.  
Applicant respectfully submits that the content of the computer readable form copy of the Sequence Listing and the paper copy previously submitted herewith is the same. No new matter has been added.
- A copy of the Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated September 3, 2002.

With the filing of these documents, it is submitted that the application is now complete and in form for examination. Accordingly, such examination and favorable action are earnestly solicited.

Respectfully submitted,

*Jules E. Goldberg*  
Jules E. Goldberg - Reg. No. 24,408  
Reed Smith LLP  
599 Lexington Avenue  
New York, NY 10022

November 4, 2002  
Tel. No. (212) 521-5400  
  
Enclosures:  
- as listed above -



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/042,703	03/21/2002	Tadahisa Sato	JG-YY-5032C/500569.20090

Jules E. Goldberg  
Reed Smith, LLP  
17th Floor  
375 Park Avenue  
New York, NY 10152



CONFIRMATION NO. 3077

FORMALITIES LETTER



\*OC00000008722388\*

Date Mailed: 09/03/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

**DOCKET**

DUE NOV. 3, 2002 Sequence Listing Docket  
March 3, 2003 Sequence Listing Docket

*HA*  
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY